Idiopathic pulmonary arterial hypertension

DMM Disease Models and Mechanisms

Volumn 3, Issue 5-6, 2010, Pages 268-273

  Firth, Amy L ^a   Mandel, Jess ^a   Yuan, Jason X J ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7,8 DIHYDRO 5 [2 [[ALPHA (3 PYRIDYL)BENZYLIDENE]AMINOOXY]ETHYL] 1 NAPHTHYLOXYACETIC ACID; AMLODIPINE; ATORVASTATIN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; MONOCROTALINE; NIFEDIPINE; PROSTACYCLIN; SILDENAFIL; SIMVASTATIN; UNIPROST;

ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL FEATURE; CLINICAL RESEARCH; DISEASE COURSE; DISEASE MODEL; DNA MODIFICATION; HUMAN; HYPOXIA; IDIOPATHIC DISEASE; IDIOPATHIC PULMONARY HYPERTENSION; LUNG RESECTION; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR;

ANIMALS; ARTERIES; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; HUMANS; HYPERTENSION, PULMONARY; MONOCROTALINE;

ANIMALIA;

EID: 77952192354     PISSN: 17548403     EISSN: 17548411     Source Type: Journal    
DOI: 10.1242/dmm.003616     Document Type: Article

References (55)

1. Beppu, H., Ichinose, F., Kawai, N., Jones, R. C., Yu, P. B., Zapol, W. M., Miyazono, K., Li, E. and Bloch, K. D. (2004). BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol. 287, L1241-L1247. (Pubitemid 39507203)
2. Christman, B. W., McPherson, C. D., Newman, J. H., King, G. A., Bernard, G. R., Groves, B. M. and Loyd, J. E. (1992). An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N. Engl. J. Med. 327, 70-75.
3. Das, M., Bouchey, D. M., Moore, M. J., Hopkins, D. C., Nemenoff, R. A. and Stenmark, K. R. (2001). Hypoxia-induced proliferative response of vascular adventitial fibroblasts is dependent on G protein-mediated activation of mitogen-activated protein kinases. J. Biol. Chem. 276, 15631-15640. (Pubitemid 37391590)
4. Davies, N. W., Standen, N. B. and Stanfield, P. R. (1991). ATP-dependent potassium channels of muscle cells: their properties, regulation, and possible functions. J. Bioenerg. Biomembr. 23, 509-535.
5. Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J. L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., Gibbs, J. S. et al. (2009). Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur. Heart J. 30, 2493-2537.
6. Giaid, A. (1998). Nitric oxide and endothelin-1 in pulmonary hypertension. Chest 114, 208S-212S.
7. Girgis, R. E., Li, D., Zhan, X., Garcia, J. G., Tuder, R. M., Hassoun, P. M. and Johns, R. A. (2003). Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am. J. Physiol. Heart Circ. Physiol. 285, H938-H945. (Pubitemid 37048146)
8. Girgis, R. E., Mozammel, S., Champion, H. C., Li, D., Peng, X., Shimoda, L., Tuder, R. M., Johns, R. A. and Hassoun, P. M. (2007). Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J. Physiol. Lung Cell. Mol. Physiol. 292, L1105-L1110. (Pubitemid 47084854)
9. Greenway, S., van Suylen, R. J., Du Marchie Sarvaas, G., Kwan, E., Ambartsumian, N., Lukanidin, E. and Rabinovitch, M. (2004). S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am. J. Pathol. 164, 253-262. (Pubitemid 38364609)
10. Gust, R. and Schuster, D. P. (2001). Vascular remodeling in experimentally induced subacute canine pulmonary hypertension. Exp. Lung Res. 27, 1-12. (Pubitemid 32056097)
11. Hamidi, S. A., Prabhakar, S. and Said, S. I. (2008). Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur. Respir. J. 31, 135-139.
12. Hessel, M. H., Steendijk, P., den Adel, B., Schutte, C. I. and van der Laarse, A. (2006). Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am. J. Physiol. Heart Circ. Physiol. 291, H2424-H2430.
13. Hirenallur, S. D., Haworth, S. T., Leming, J. T., Chang, J., Hernandez, G., Gordon, J. B. and Rusch, N. J. (2008). Upregulation of vascular calcium channels in neonatal piglets with hypoxia-induced pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 295, L915-L924.
14. Ivy, D. D., McMurtry, I. F., Colvin, K., Imamura, M., Oka, M., Lee, D.-S., Gebb, S. and Jones, P. L. (2005). Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension. Circulation 111, 2988-2996. (Pubitemid 40814193)
15. Jing, Z. C., Jiang, X., Han, Z. Y., Xu, X. Q., Wang, Y., Wu, Y., Lv, H., Ma, C. R., Yang, Y. J. and Pu, J. L. (2009). Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension. Eur. Respir. J. 33, 1354-1360.
16. Lai, Y. J., Pullamsetti, S. S., Dony, E., Weissmann, N., Butrous, G., Banat, G. A., Ghofrani, H. A., Seeger, W., Grimminger, F. and Schermuly, R. T. (2008). Role of the prostanoid EP4 receptor in iloprost-mediated vasodilatation in pulmonary hypertension. Am. J. Respir. Crit. Care Med. 178, 188-196. (Pubitemid 351957777)
17. Lane, K. B., Machado, R. D., Pauciulo, M. W., Thomson, J. R., Phillips, J. A., III, Loyd, J. E., Nichols, W. C., Trembath, R. C. and The IPPH Consortium (2000). Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. Nat. Genet. 26, 81-84.
18. Lang, I., Gomez-Sanchez, M., Kneussl, M., Naeije, R., Escribano, P., Skoro-Sajer, N. and Vachiery, J. L. (2006). Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 129, 1636-1643. (Pubitemid 43894997)
19. Long, L., MacLean, M. R., Jeffery, T. K., Morecroft, I., Yang, X., Rudarakanchana, N., Southwood, M., James, V., Trembath, R. C. and Morrell, N. W. (2006). Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ. Res. 98, 818-827. (Pubitemid 43755266)
20. Long, L., Crosby, A., Yang, X., Southwood, M., Upton, P. D., Kim, D. K. and Morrell, N. W. (2009). Altered bone morphogenetic protein and transforming growth factor-beta signaling in rat models of pulmonary hypertension: potential for activin receptor-like kinase-5 inhibition in prevention and progression of disease. Circulation 119, 566-576.
21. Machado, R. D., Aldred, M. A., James, V., Harrison, R. E., Patel, B., Schwalbe, E. C., Gruenig, E., Janssen, B., Koehler, R., Seeger, W. et al. (2006). Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum. Mutat. 27, 121-132. (Pubitemid 43238027)
22. Masri, F. A., Xu, W., Comhair, S. A., Asosingh, K., Koo, M., Vasanji, A., Drazba, J., Anand-Apte, B. and Erzurum, S. C. (2007). Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L548-L554. (Pubitemid 47358814)
23. McMurtry, M. S., Bonnet, S., Michelakis, E. D., Haromy, A. and Archer, S. L. (2007). Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamcyin-atorvastatin- simvastatin study. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L933-L940. (Pubitemid 47572241)
24. Mouchaers, K. T., Schalij, I., Versteilen, A. M., Hadi, A. M., van Nieuw Amerongen, G. P., van Hinsbergh, V. W., Postmus, P. E., van der Laarse, W. J. and Vonk-Noordegraaf, A. (2009). Endothelin receptor blockade combined with phosphodiesterase-5 inhibition increases right ventricular mitochondrial capacity in pulmonary arterial hypertension. Am. J. Physiol. Heart Circ. Physiol. 297, H200-H207.
25. Nishimura, T., Faul, J. L., Berry, G. J., Vaszar, L. T., Qiu, D., Pearl, R. G. and Kao, P. N. (2002). Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 166, 1403-1408. (Pubitemid 35292709)
26. Nishimura, T., Vaszar, L. T., Faul, J. L., Zhao, G., Berry, G. J., Shi, L., Qiu, D., Benson, G., Pearl, R. G. and Kao, P. N. (2003). Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 108, 1640-1645. (Pubitemid 37187793)
27. Obata, H., Sakai, Y., Ohnishi, S., Takeshita, S., Mori, H., Kodama, M., Kangawa, K., Aizawa, Y. and Nagaya, N. (2008). Single injection of a sustained-release prostacyclin analog improves pulmonary hypertension in rats. Am. J. Respir. Crit Care Med. 177, 195-201.
28. Pan, L. C., Wilson, D. W. and Segall, H. J. (1993). Strain differences in the response of Fischer 344 and Sprague-Dawley rats to monocrotaline induced pulmonary vascular disease. Toxicology 79, 21-35. (Pubitemid 23116625)
29. Pozeg, Z. I., Michelakis, E. D., McMurtry, M. S., Thebaud, B., Wu, X. C., Dyck, J. R., Hashimoto, K., Wang, S., Moudgil, R., Harry, G. et al. (2003). In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 107, 2037-2044. (Pubitemid 36506080)
30. Rabinovitch, M. (2001). Linking a serotonin transporter polymorphism to vascular smooth muscle proliferation in patients with primary pulmonary hypertension. J. Clin. Invest. 108, 1109-1111. (Pubitemid 32995368)
31. Runo, J. R. and Loyd, J. E. (2003). Primary pulmonary hypertension. Lancet 361, 1533-1544.
32. Satoh, M. and Satoh, A. (2008). 3-Hydroxy-3-methylglutaryl (HMG)-COA reductase inhibitors and phosphodiesterase type V inhibitors attenuate right ventricular pressure and remodeling in a rat model of pulmonary hypertension. J. Pharm. Pharm. Sci. 11, 118s-130s.
33. Savale, L., Tu, L., Rideau, D., Izziki, M., Maitre, B., Adnot, S. and Eddahibi, S. (2009). Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir. Res. 10, 6.
34. Simonneau, G., Robbins, I. M., Beghetti, M., Channick, R. N., Delcroix, M., Denton, C. P., Elliott, C. G., Gaine, S. P., Gladwin, M. T., Jing, Z. C. et al. (2009). Updated clinical classification of pulmonary hypertension. J. Am. Coll. Cardiol. 54, S43-S54.
35. Song, Y., Jones, J. E., Beppu, H., Keaney, J. F., Jr, Loscalzo, J. and Zhang, Y.-Y. (2005). Increased susceptibility to pulmonary hypertension in heterozygous BMPR2-mutant mice. Circulation 112, 553-562. (Pubitemid 41060796)
36. Song, Y., Coleman, L., Shi, J., Beppu, H., Sato, K., Walsh, K., Loscalzo, J. and Zhang, Y. Y. (2008). Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice. Am J. Physiol. Heart Circ. Physiol. 295, H677-H690.
37. Spiekerkoetter, E., Alvira, C. M., Kim, Y. M., Bruneau, A., Pricola, K. L., Wang, L., Ambartsumian, N. and Rabinovitch, M. (2008). Reactivation of gammaHV68 induces neointimal lesions in pulmonary arteries of S100A4/Mts1-overexpressing mice in association with degradation of elastin. Am. J. Physiol. Lung Cell. Mol. Physiol. 294, L276-L289. (Pubitemid 351253364)
38. Stanbrook, H. S., Morris, K. G. and McMurtry, I. F. (1984). Prevention and reversal of hypoxic pulmonary hypertension by calcium antagonists. Am. Rev. Resp. Dis. 130, 81-85. (Pubitemid 14092986)
39. Steiner, M. K., Syrkina, O. L., Kolliputi, N., Mark, E. J., Hales, C. A. and Waxman, A. B. (2009). Interleukin-6 overexpression induces pulmonary hypertension. Circ. Res. 104, 236-244.
40. Stenmark, K. R., Davie, N., Frid, M., Gerasimovskaya, E. and Das, M. (2006). Role of the adventitia in pulmonary vascular remodeling. Physiology (Bethesda) 21, 134-145. (Pubitemid 43752509)
41. Stenmark, K. R., Meyrick, B., Galie, N., Mooi, W. J. and McMurtry, I. F. (2009). Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am. J. Physiol. Lung Cell. Mol. Physiol. 297, L1013-L1032.
42. Taraseviciene-Stewart, L., Kasahara, Y., Alger, L., Hirth, P., McMahon, G., Waltenberger, J., Voelkel, N. F. and Tuder, R. M. (2001). Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15, 427-438. (Pubitemid 32141434)
43. Taraseviciene-Stewart, L., Scerbavicius, R., Choe, K.-H., Cool, C., Wood, K., Tuder, R. M., Burns, N., Kasper, M. and Voelkel, N. F. (2006). Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 291, L668-L676. (Pubitemid 44498478)
44. Thomas, M., Docx, C., Holmes, A. M., Beach, S., Duggan, N., England, K., Leblanc, C., Lebret, C., Schindler, F., Raza, F. et al. (2009). Activin-like kinase 5 (ALK5) mediates abnormal proliferation of vascular smooth muscle cells from patients with familial pulmonary arterial hypertension and is involved in the progression of experimental pulmonary arterial hypertension induced by monocrotaline. Am. J. Pathol. 174, 380-389.
45. Tuder, R. M., Groves, B., Badesch, D. B. and Voelkel, N. F. (1994). Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am. J. Pathol. 144, 275-285. (Pubitemid 24165948)
46. van Albada, M. E., van Veghel, R., Cromme-Dijkhuis, A. H., Schoemaker, R. G. and Berger, R. M. (2006). Treprostinil in advanced experimental pulmonary hypertension: beneficial outcome without reversed pulmonary vascular remodeling. J. Cardiovasc. Pharmacol. 48, 249-254.
47. 2+ entry. J. Pharmacol. Sci. 108, 71-78.
48. West, J., Fagan, K., Steudel, W., Fouty, B., Lane, K., Harral, J., Hoedt-Miller, M., Tada, Y., Ozimek, J., Tuder, R. et al. (2004). Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ. Res. 94, 1109-1114. (Pubitemid 38579706)
49. White, R. J., Meoli, D. F., Swarthout, R. F., Kallop, D. Y., Galaria, I. I., Harvey, J. L., Miller, C. M., Blaxall, B. C., Hall, C. M., Pierce, R. A. et al. (2007). Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L583-L590.
50. Yu, P. B., Deng, D. Y., Beppu, H., Hong, C. C., Lai, C., Hoyng, S. A., Kawai, N. and Bloch, K. D. (2008). Bone morphogenetic protein (BMP) type II receptor is required for BMP-mediated growth arrest and differentiation in pulmonary artery smooth muscle cells. J. Biol. Chem. 283, 3877-3888.
51. Yu, Y., Keller, S. H., Remillard, C. V., Safrina, O., Nicholson, A., Zhang, S. L., Jiang, W., Vangala, N., Landsberg, J. W., Wang, J. Y. et al. (2009). A functional single-nucleotide polymorphism in the TRPC6 gene promoter associated with idiopathic pulmonary arterial hypertension. Circulation 119, 2313-2322.
52. Yuan, J. X., Aldinger, A. M., Juhaszova, M., Wang, J., Conte, J. V., Jr, Gaine, S. P., Orens, J. B. and Rubin, L. J. (1998). Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 98, 1400-1406. (Pubitemid 28462800)
53. Zhao, L., Mason, N. A., Morrell, N. W., Kohonazarov, B., Sadykov, A., Maripov, A., Mirrakhimov, M. M., Aldashev, A. and Wilkins, M. R. (2001). Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104, 424-428. (Pubitemid 32678272)
54. Zhao, L., Sebkhi, A., Ali, O., Wojciak-Stothard, B., Mamanova, L., Yang, Q., Wharton, J. and Wilkins, M. R. (2009). Simvastatin and sildenafil combine to attenuate pulmonary hypertension. Eur. Respir. J. 34, 948-957.
55. Zierer, A., Voeller, R. K., Melby, S. J., Steendijk, P. and Moon, M. R. (2009). Impact of calcium-channel blockers on right heart function in a controlled model of chronic pulmonary hypertension. Eur. J. Anaesthesiol. 26, 253-259.